
In a unique, retreat-style setting, health systems leaders had close conversations around best practices, wins, struggles, and solutions.
Importance of transparency when addressing a changing 340B environment.
Date
September 12, 2022
By: Heather Easterling and Andrew Wilson
Read time: 1 minute
Since 2020, drug manufacturers have implemented policies restricting the purchase of 340B-priced drugs for covered entities when dispensing through contract pharmacies and the result is contributing to financial losses for safety-net hospitals.
Watch the 340B Tips, Tricks, and Traps webinar as we explore this ever-changing environment and how transparency is at the center of it all.
In a unique, retreat-style setting, health systems leaders had close conversations around best practices, wins, struggles, and solutions.
Discover three key takeaways from a recent C-suite roundtable discussing the benefits and challenges of central fill for health systems.
Learn how McKesson is helping advance the 340B program through strategic customer engagement and insights.
Explore key trends and strategic recommendations from our experts to help you achieve more.
With available labor resources dwindling and a shrinking pipeline, health systems must find creative solutions for better using the personnel they have.
Three key benefits of exploring nontraditional partnerships with your distributor to achieve more.
A closer partnership between pharmacy and RCM teams may lead to increased financial stability and improved quality of care.